Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)
Authors:
- 14 September 2017
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 25 (2) , 118-125
Abstract
Summary: The efficacy and safety of an investigational combination of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) plus sofosbuvir (SOF) ± ribavirin (RBV) in patients with HCV genotype 2 or 3 infection with or without cirrhosis was evaluated. Patients with HCV genotype 3 infection without cirrhosis were randomized to receive OBV/PTV/r + SOF ± RBV for 12 weeks; OBV/PTV/r + SOF + RBV was administered to genotype 3‐infected patients with cirrhosis for 12 weeks and to genotype 2‐infected patients without cirrhosis for either 6 or 8 weeks. Efficacy was assessed by sustained virologic response [HCV RNA <25 IU/mL] 12 weeks post‐treatment (SVR12). Safety was assessed in all treated patients. In patients with genotype 3 infection with or without cirrhosis treated with 12 weeks of OBV/PTV/r + SOF ± RBV, the overall SVR12 rate was 98% (50/51), with no virologic failures. Patients with genotype 2 infection treated with OBV/PTV/r + SOF + RBV had SVR12 rates of 90% (9/10) and 44% (4/9) following 8‐ and 6‐week treatment durations, respectively; failure to achieve SVR12 for these patients was due to relapse without baseline or treatment‐emergent resistance‐associated substitutions. Thus, the investigational combination of OBV/PTV/r with SOF ± RBV was well tolerated and achieved high SVR rates with no virologic failures in patients with genotype 3 infection. Combining direct‐acting antivirals with complementary mechanisms of action and different viral targets may be an effective treatment strategy that may allow for shorter durations of therapy.Keywords
Funding Information
- AbbVie (NCT02292719)
This publication has 30 references indexed in Scilit:
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosisJournal of Hepatology, 2017
- Short‐duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trialHepatology, 2016
- EASL Recommendations on Treatment of Hepatitis C 2015Journal of Hepatology, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infectionJournal of Infection, 2014
- Global distribution and prevalence of hepatitis C virus genotypesHepatology, 2014
- HCV Genotype 3 Is Associated With an Increased Risk of Cirrhosis and Hepatocellular Cancer in a National Sample of U.S. Veterans With HCVHepatology, 2014
- Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trialJournal of Hepatology, 2013
- Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis CJournal of Hepatology, 2009